Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Market Update 2 December

Bell Direct
December 2, 2019

November Market Overview

Bell Direct
November 29, 2019

Morning Bell 27 November

Bell Direct
November 27, 2019

Morning Bell 26 November

Bell Direct
November 26, 2019

Market Update 22 November

Bell Direct
November 22, 2019

Closing Bell 20 November

Bell Direct
November 20, 2019

Morning Bell 20 November

Bell Direct
November 20, 2019

Closing Bell 19 November

Bell Direct
November 19, 2019

Morning Bell 19 November

Bell Direct
November 19, 2019

Closing Bell 18 November

Jessica Amir
November 18, 2019

Morning Bell 18 November

Bell Direct
November 18, 2019